Search Results for "Rnai Therapy For Fshd"
Original Source: Duchenne muscular dystrophy - DMD
Duchenne muscular dystrophy (DMD) is a severely debilitating childhood neuromuscular disease that affects 1 in 3,500 live male births. This rare disease is caused by mutations in the dystrophin gene, resulting in the absence or defect of the dystrophin p...
Matching Channels
Neoadjuvant therapy is the administration of therapeutic agents before the main treatment. One example is neoadjuvant hormone therapy prior to radical radiotherapy for adenocarcinoma of the prostate...
Matching News
The FSH Society Answers Questions About the New Gene for FSH Muscular Dystrophy
Boston, MA (PRWEB) January 24, 2013 Facioscapulohumeral muscular dystrophy (FSHD) is a disease most people have never heard of, even though it is one of the most common forms of muscular dystrophy....
Telomere shortening affects muscular dystrophy gene
(Medical Xpress)—Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that causes the muscles of the upper body to waste away. It is unusual in that symptoms do not usually appear unt...
Solstice Biologics says that is has solved the problem of delivering RNAi into a cell with its new 'limitless' RNAi technology. The technology employs a covalently bound molecule to form an RNAi pro-d...
Tekmira and Marina Biotech in license agreement for novel RNAi technology
Canadian RNA interference (RNAi) therapeutics developer Tekmira Pharmaceuticals (Nasdaq: TKMR) has obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleo...
[Alnylam] strengthens RNAi IP through buy of [Nucleonics]' assets
The soon-to-be defunct RNAi therapeutics company [Nucleonics Inc.] has sold its intellectual property assets, which cover broad structural features of RNAi therapeutics, to [Alnylam Pharmaceuticals In...
A recent finding by medical geneticists sheds new light on how Facioscapulohumeral Muscular Dystrophy develops and how it might be treated. More commonly known as FSHD, the devastating disease affects...
Silence raises £19 million in stock placing
Silence Therapeutics has raised £19 million to support its RNAi portfolio through a placing of 9.5 million shares, cashing in on a renewed focus on RNAi companies following AstraZeneca's recent decis...
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemophilia and ...
Efficacy for ALN-AT3, an RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia, Demonstrated in Non-Human Primate Models – Progress from the Therapeutic Program to be...
Matching PubMed Articles
Facioscapulohumeral muscular dystrophy (FSHD), is a dominantly inherited, late onset, progressive disease. At present, no treatment or prevention of symptoms are available. There is considerable clini...
Potential use of RNA interference in cancer therapy.
RNA interference (RNAi) is an evolutionary conserved mechanism for specific gene silencing. This mechanism has great potential for use in targeted cancer therapy. Understanding the RNAi mechanism has...
Camptocormia phenotype of FSHD: a clinical and MRI study on six patients.
Recently it has been postulated that there is an atypical facioscapulohumeral muscular dystrophy (FSHD) phenotype with isolated axial myopathy. Involvement of paraspinal and limb muscles was evaluated...
A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy.
Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy in adults that is foremost characterized by progressive wasting of muscles in the upper body. FSHD is associated wi...
Facioscapulohumeral muscular dystrophy : Clinical picture, atypical forms, diagnostics, genetics.
The classic phenotype of the facioscapulohumeral muscular dystrophy (FSHD) includes an initially restricted pattern of asymmetric weakness of facial and shoulder girdle muscles. Disease progression is...
